Medicare Part D coverage · naproxen · RxCUI 603103
naproxen 375 MG Delayed Release Oral Tablet
Per the CMS 2026 Part D formulary file, naproxen 375 MG Delayed Release Oral Tablet is covered by 4,771 Medicare Part D plans (94.4% of enrollable products), averaging Tier 1.8, with prior authorization required on 0% of covering formularies.
- 94.4%
- Plan coverage
- 4,771
- Plans covering
- T1.8
- Avg tier
- 0%
- Prior auth required
What the CMS Formulary Data Shows for naproxen 375 MG Delayed Release Oral Tablet
Per the CMS 2026 Part D formulary file, naproxen 375 MG Delayed Release Oral Tablet (RxNorm concept RXCUI 603103, generic name naproxen) appears on 299 distinct formulary files spanning 4,771 Medicare Part D plan offerings - 94.4% of enrollable Part D products, near-universal placement. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 1.8.
Real-world access to naproxen 375 MG Delayed Release Oral Tablet depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 44.1% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 1,344,536 Part D beneficiaries filled naproxen 375 MG Delayed Release Oral Tablet in 2023, with total plan-and-beneficiary spending of $48,825,410 and an average per-beneficiary annual cost of $36.31. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry naproxen 375 MG Delayed Release Oral Tablet today.
Coverage Details
- Formularies covering
- 299
- Plans covering
- 4,771
- Coverage rate
- 94.4%
- Tier range
- Tier 1 – Tier 4
- Average tier
- Tier 2, Generic
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 44.1% of formularies
2023 Medicare Spending
- Beneficiaries
- 1,344,536
- Total spending
- $48,825,410
- Avg per beneficiary
- $36.31
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering naproxen 375 MG Delayed Release Oral Tablet
100 Medicare Advantage plans with Part D drug coverage include this drug.
Show the next 30 plans
Showing top 50 of 100 plans.
Frequently Asked Questions
Is naproxen 375 MG Delayed Release Oral Tablet covered by Medicare Part D?
Yes, naproxen 375 MG Delayed Release Oral Tablet is covered by 4,771 Medicare Part D plans (94.4% of all Part D formularies).
What tier is naproxen 375 MG Delayed Release Oral Tablet on Medicare Part D plans?
naproxen 375 MG Delayed Release Oral Tablet averages Tier 1.8 across Part D plans, ranging from Tier 1 to Tier 4.
Does naproxen 375 MG Delayed Release Oral Tablet require prior authorization?
0% of Part D formularies require prior authorization for naproxen 375 MG Delayed Release Oral Tablet. Step therapy: 0%. Quantity limits: 44.1%.
How much does Medicare spend on naproxen 375 MG Delayed Release Oral Tablet?
In 2023, total Medicare Part D spending on naproxen 375 MG Delayed Release Oral Tablet was $48,825,410, covering 1,344,536 beneficiaries. The average spend per beneficiary was $36.31.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
Similar prior-authorization rate
- metronidazole 10 MG/ML Topical Cream [Noritate] 0% PA
- 24 HR minocycline 40 MG Extended Release Oral Capsule [Emrosi] 0% PA
- buspirone hydrochloride 10 MG Oral Capsule [Bucapsol] 0% PA
- diflunisal 375 MG Oral Tablet [Dolobid] 0% PA
- hydrocortisone 1 MG/ML Oral Solution [Khindivi] 0% PA
- indomethacin 50 MG Rectal Suppository [Indocin] 0% PA